Image de couverture de livre

Real‐World Experience of 3‐Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Hideyuki Nakajima, Masahiro Kamata, Yoshiki Okada, Shoya Suzuki, Makoto Ito, Ayu Watanabe, Shota Egawa, Chika Chijiwa, Azusa Hiura, Yayoi Tomura, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Yayoi Tada
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Experimental Dermatology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long‐Term Treatment With Dupilumab: A Single‐Center Retrospective Study
par: Ayu Watanabe, et autres
Publié: (2025)

Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world
par: Ayu Watanabe, et autres
Publié: (2024)

A 308‐nm Excimer Lamp Ameliorates MC903 ‐Induced Atopic Dermatitis With Reductions of Intraepidermal Nerve Fiber Density and Expression of Thymic Stromal Lymphopoietin
par: Thalita Bastos, et autres
Publié: (2026)

Serum interleukin‐10 level is increased and correlated positively with disease severity in patients with dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid
par: Shoya Suzuki, et autres
Publié: (2024)

Interleukin‐23 inhibitors decrease Fibrosis‐4 index in psoriasis patients with elevated Fibrosis‐4 index but not interleukin‐17 inhibitors
par: Ryosuke Takeshima, et autres
Publié: (2024)

Combined Maxacalcitol/Betamethasone Butyrate Propionate Ointment Possesses Long‐Term Sustained Effects of Inducing Regulatory T Cells and Downregulating the Th17 Response, Even After Discontinuation of Its Application in Imiquimod‐Induced Psoriasiform Dermatitis
par: Teruo Shimizu, et autres
Publié: (2025)

308‐nm excimer light is effective for palmoplantar pustulosis regardless of the presence or absence of focal infection: Single‐center real‐world experience of treatment for palmoplantar pustulosis
par: Yoshiko Niimura, et autres
Publié: (2024)

Effects of Narrowband Ultraviolet B Therapy on the Skin Barrier in a Murine Model of Dry Skin
par: Sumika Toyama, et autres
Publié: (2025)

Combination Therapy With Upadacitinib and Dupilumab for Severe Atopic Dermatitis
par: Amaia Barrutia‐Etxebarria, et autres
Publié: (2025)

Encuentro multicultural en el arte de barniz de Pasto o la laca del Virreinato del Perú
par: Yayoi Kawamura Kawamura
Publié: (2018)

Characteristics and Risk Factors of Dupilumab‐Associated Head and Neck Dermatitis in Patients With Atopic Dermatitis
par: Zifan Li, et autres
Publié: (2026)

Dupilumab Treatment for Atopic Dermatitis Is Associated With Decreased Risk of Otitis Media and Related Surgical Procedures: A Retrospective Cohort Study
par: Matthew H. Lanehart, et autres
Publié: (2025)

Concordance Between Patient‐ and Physician‐Reported Improvement With Dupilumab in Atopic Dermatitis
par: Geena Conde, et autres
Publié: (2026)

Dupilumab in Combination With JAK Inhibitor for Refractory Moderate‐to‐Severe Atopic Dermatitis
par: Xiaoting Song, et autres
Publié: (2024)

Real‐World Experience of Dupilumab in Children and Adolescents With Atopic Dermatitis in Argentina
par: Margarita Larralde, et autres
Publié: (2025)

Long‐Term Safety and Efficacy of Dupilumab in Pediatric Atopic Dermatitis Patients
par: Hilla Bauch-Eigner, et autres
Publié: (2025)

Real‐World Efficacy and Safety of Dupilumab for Atopic Dermatitis in the Israeli Population
par: Raz Tshuva, et autres
Publié: (2025)

Severe Allergic Contact Dermatitis to Hair Dye in a Patient With Atopic Dermatitis During Dupilumab Therapy
par: Alessandra Chiei Gallo, et autres
Publié: (2025)

Successful Use of Dupilumab in the Treatment of Acquired Perforating Dermatosis Associated with Atopic Dermatitis
par: Niccolò Gori, et autres
Publié: (2024)

Dupilumab‐Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib
par: Grigorios Theodosiou, et autres
Publié: (2026)

The Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged Under 12‐Years
par: Laura Wheller, et autres
Publié: (2026)

A Pediatric Case of Severe Atopic Dermatitis on Dupilumab Treatment and Pulmonary Tuberculosis
par: Maria Efenesia Baffa, et autres
Publié: (2025)

Interleukin‐22 and Interleukin‐18 as Potential Blood Biomarkers in Dupilumab‐Treated Atopic Dermatitis
par: Ayano Fukushima‐Nomura, et autres
Publié: (2026)

Real‐World Use of Dupilumab in Atopic Dermatitis: Observational Study Results Linked to SNDS
par: Alain Dupuy, et autres
Publié: (2026)

Evaluating Outcomes of Live‐Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis
par: Grace Eleanor Sessler Bruess, et autres
Publié: (2025)

Increased Risk of Cutaneous T‐Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis
par: Jenna Mandel, et autres
Publié: (2024)

Investigating human pregnancy with trophoblast organoids
par: Ida Calvi, et autres
Publié: (2026)

Serum Eosinophil‐Derived Neurotoxin (EDN) as a Biomarker for Treatment Response in Atopic Dermatitis
par: J. I. Olydam, et autres
Publié: (2026)

Effect of Dupilumab Therapy on Patch Test Results for Atopic Contact Dermatitis: A Systematic Review
par: Dennis Chu, et autres
Publié: (2025)

An Observational Study of Early Treatment Response and Predictors of Dupilumab in the Treatment of Moderate‐to‐Severe Atopic Dermatitis
par: Sisi Deng, et autres
Publié: (2024)

Interpolant of truncated multiple zeta functions
par: Ihara, Kentaro, et autres
Publié: (2024)

Chromatic number of random graphs: an approach using a recurrence relation
par: Abe, Yayoi, et autres
Publié: (2024)

Atopic Dermatitis
Publié: (2026)

Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders
par: Mutong Zhao, et autres
Publié: (2024)

Dupilumab‐Associated Ocular Surface Disease in Pediatric Atopic Dermatitis: A Single‐Center Asian Experience
par: Amanda Xin Yi Yap, et autres
Publié: (2024)

Successful Use of Dupilumab in Atopic Dermatitis‐Like Graft‐Versus‐Host Disease: A Case Report
par: Qingjun Liao, et autres
Publié: (2024)

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis
par: Paul Sun Woo Kim, et autres
Publié: (2026)

Formononetin From Sophora flavescens Aiton Alleviates Atopic Dermatitis by Suppressing Neutrophil Extracellular Traps
par: Lin Cheng, et autres
Publié: (2025)

Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real‐Life Study
par: Edoardo Mortato, et autres
Publié: (2025)

Predictive Factors of Super‐Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real‐World Monocentric Study
par: Edoardo Mortato, et autres
Publié: (2026)